Tobias J. Grob

Tobias J. Grob

Auto-generated profile, based on publicly available information

Tobias J. Grob

Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2014 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
AQAlexander Quaas
Alexander Quaas
TOTheresa Oldopp
Theresa Oldopp
LTLars Tharun
Lars Tharun
CKCatina Klingenfeld
Catina Klingenfeld
TKTill Krech
Till Krech
TGTobias J. Grob
Tobias J. Grob

19 May 2012 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TGTobias J. Grob
Tobias J. Grob
UHUwe Heilenkötter
Uwe Heilenkötter
SGStefan Geist
Stefan Geist
PPPeter Paluchowski
Peter Paluchowski
CWChristian Wilke
Christian Wilke
ALAnnette Lebeau
Annette Lebeau

1 December 2012 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
TGTobias J Grob
Tobias J Grob
IKIvonne Kannengiesser
Ivonne Kannengiesser
MTMaria C Tsourlakis
Maria C Tsourlakis
DADjordje Atanackovic
Djordje Atanackovic
AKAlexandra M Koenig
Alexandra M Koenig
WWWaldemar Wilczak
Waldemar Wilczak
The HER2 protein, encoded by the ERBB2 gene, is a molecular target for the treatment of breast and gastric cancer by monoclonal antibodies or tyrosine kinase inhibitors. While intratumoral heterogeneity of ERBB2 amplification is rare in breast cancer it is reported to be frequent in bladder and colorectal cancer. To address the potential heterogeneity of the HER2 status in adenocarcinomas, squamous cell carcinomas and large cell undifferentiated carcinomas of the lung, 590 tumors were analyzed for HER2 overexpression and ERBB2 amplification using FDA-approved reagents for immunohistochemistry and fluorescence in-situ hybridization (FISH). Moderate and strong immunostaining (2+, 3+) was seen in 10% of the tumors. ERBB2 amplification was found in 17 (3%) lung cancer patients including 10 cases (2%) with high-level amplification forming gene clusters. ERBB2 amplification was significantly related to histologic subtype and tumor grade, resulting in 12% ERBB2 amplified tumors in the subgroup of high-grade adenocarcinomas. Heterogeneity was analyzed in all highly amplified tumors. For this purpose, all available tumor tissue blocks from these patients were evaluated. Heterogeneity of ERBB2 amplification was found in 4 of 10 tumors as assessed by FISH. These included two tumors with a mixture of low-level and high-level amplification and two tumors with non-amplified tumor areas next to regions with high-level ERBB2 amplification. High-level ERBB2 amplification occurs in a small fraction of lung cancers with a strong propensity to high-grade adenocarcinomas. Heterogeneity of amplification may limit the utility of anti-HER2 therapy in some of these tumors. Further attempts to assess the utility of HER2-targeting therapy in homogeneously amplified lung cancers appear to be justified.

1 March 2013 in Lung Cancer
Verified
Journal Article
Closed access
TGTobias J. Grob
Tobias J. Grob
THTobias Hoenig
Tobias Hoenig
TCTill S. Clauditz
Till S. Clauditz
DADjordje Atanackovic
Djordje Atanackovic
AKAlexandra M. Koenig
Alexandra M. Koenig
WWWaldemar Wilczak
Waldemar Wilczak

20 February 2014 in Allgemein- und Viszeralchirurgie up2date
Verified
Journal Article
Closed access
PDF file
TGT. Grob
T. Grob
In den letzten Jahren nimmt die Rolle der molekularen Biomarker in der Diagnostik und der Therapie von malignen gastrointestinalen Tumoren eine immer wichtigere Stellung ein. Insbesondere die Bestimmung sogenannter prädiktiver Biomarker, welche ein mögliches Therapieansprechen voraussagen, gehört mittlerweile zum Standard der pathologischen Aufarbeitung dieser Malignome.